Steatosis Grade is the Most Important Risk Factor for Development of Endothelial Dysfunction in NAFLD

Medicine (United States)

Volumn 95, Issue 14, 2016, Pages

  Sapmaz, Ferdane ^a   Uzman, Metin ^a   Basyigit, Sebahat ^a   Ozkan, Selcuk ^a   Yavuz, Bunyamin ^a   Yeniova, Abdullah ^a   Kefeli, Ayse ^a   Asilturk, Zeliha ^a   Nazligül, Yasar ^a  

^a Pediatric Surgery Keçiören Education and Training Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTERY BLOOD FLOW; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; BLOOD VESSEL PARAMETERS; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ASSOCIATION; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; FIBROSIS 4 SCORE; FLOW MEDIATED DILATATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THROMBOCYTE; AGED; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIUM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84964663113     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003280     Document Type: Article

References (32)

1. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883-889.
2. Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2015;41:65-76.
3. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844-1850.
4. Yang HR, Kim HR, Kim MJ, et al. Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18:1525-1530.
5. Vijay Laxmi M, Mouen K, Naga C. Non-Alcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep 2009; 11:50-55.
6. Guha IN, Parkes J, Roderick PR, et al. Non-invasive markers associated with liver fibrosis in non-Alcoholic fatty liver disease. Gut. 2006;55:1650-1660.
7. Lu H, Liu H, Hu F, et al. Independent association between nonalcoholic fatty liver disease and cardiovascular disease: a systematic review and meta-Analysis. Int J Endocrinol. 2013;2013: 1-8.
8. Al-Qaisi M, Kharbanda RK, Mittal TK, et al. Measurement of endothelial function and its clinical utility for cardiovascular risk. Vasc Health Risk Manag. 2008;4:647e652.
9. Senturk O, Kocaman O, Hulagu S, et al. Endothelial dysfunction in Turkish patients with non-Alcoholic fatty liver disease. Intern Med J. 2008;38:183-189.
10. Fan Y, Wei F1, Zhou Y1, et al. Association of nonalcoholic fatty liver disease with impaired endothelial function by flow-mediated dilation: a meta-Analysis. Hepatol Res 2015. [Epub ahead of print].
11. Katz SD, Hryniewicz K, Hriljac I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005;111:310e314.
12. Wang T, Chen XH, Yin QF. The relation between endothelial function and insulin resist in nonalcoholic fatty liver disease. Med Info Med Surg. 2002;22:4-11.
13. Vlachopoulos C, Manesis E, Baou K, et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: a pilot study. Am J Hypertens. 2010;23:1183-1189.
14. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Clin Res Br Med J. 1986;292:13-15.
15. Mancia G, Fagard R, Narkiewicz K, et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31:1925-1938.
16. WHO/IASO/IOTF. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Sydney: Health Communications Australia Pty Ltd; 2000.
17. American Diabetes Association (ADA). Clinical practice recommendations. Diabetes Care. 2007;30(Suppl 1):S42-S47.
18. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
19. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-419.
20. Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954-961.
21. Wai C, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526.
22. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-1325.
23. Neunteufl T, Katzenschlager R, Hassan A, et al. Systemic endothe-lial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis. 1997;129:111-118.
24. Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall; 1991:285.
25. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of nonalcoholic fatty liver disease. QJM. 2010;103:71-83.
26. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-923.
27. Zhao QH, Li X, Fu WG, et al. Evaluation of brachial artery endothelial function in patients with nonalcoholic fatty liver disease by ultrasonography. J Med Imag. 2006;16:824-826.
28. Peretz A, Leota DF, Sullivan JH, et al. Flow mediated dilation of the brachial artery: an investigation of methods requiring further standardization. BMC Cardiovasc Disord. 2007;21:7-11.
29. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in nonalcoholic fatty liver disease: causal effect or epipheno-menon? Diabetologia. 2008;51:1947-1953.
30. Vlachopoulos C, Manesis E, Baou K, et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: a pilot study. Am J Hypertens. 2010;23:1183-1189.
31. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42:473-480.
32. Shimbo D, Grahame-Clarke C, Miyake Y, et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis. 2007;192: 197-203.